Undisclosed Clin0 liver fibrosis/NASH; undisclosed Clin0 lung conditions/influenza; undisclosed Clin0 IBD; 5 undisclosed programs RD immuno-oncology, polycystic kidney disease, obesity, diabetes
Abalone Bio is developing antibody drugs that target receptors on the surface of cells to treat diseases. G-protein coupled receptors (GPCRs) are important for cellular health and frequently get disrupted in disease, yet many remain undruggable by small molecules. Antibodies are also limited to only blocking, not activating, GPCRs. Abalone is changing this by finding both activating or inhibiting bioactive antibodies that target GPCRs. To discover these antibodies, Abalone is combining engineered living cells with data-driven computation, which is compatible with different types of antibodies. Abalone’s first therapeutic focus is immune system regulators that cause inflammatory diseases and cancer.